GHRS
NASDAQ
$27.53
GH Research PLC (GHRS)
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $39.50 (+43.48%)
Market Cap
$1.67B
EPS 5Y CAGR
+89.13%
FCF 5Y CAGR
+101.54%
Free Cash Flow Yield
-2.79%
Price Chart
Valuation
Market Cap$1.67B
P/B6.98
Profitability
EBITDA-$59M
EPS-$0.91
Financial Health
Debt-to-Equity0.2%
Free Cash Flow Yield-2.79%
Growth & Risk
EPS 5Y CAGR+89.13%
FCF 5Y CAGR+101.54%
Beta (5Y)0.92
Sharpe Ratio0.94